share_log

中國生物製藥：自願公告 - 根據限制性股份獎勵計劃購買股份

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME

Hong Kong Stock Exchange ·  Apr 15 04:59
Summary by Moomoo AI
中國生物製藥有限公司（「本公司」）於2024年4月15日根據2018年1月5日採納的限制性股份獎勵計劃，透過受託人從市場購買了5,000,000股股份，佔已發行股份總數約0.027%，每股平均代價為2.68港元，總代價約為13,402,500港元。該批股份將由受託人代獲選參與者以信託持有。本公司董事會將繼續檢討及決定未來根據該計劃授予的股份數目及購買的股份數目。公告由公司主席謝其潤於同日發出。
中國生物製藥有限公司（「本公司」）於2024年4月15日根據2018年1月5日採納的限制性股份獎勵計劃，透過受託人從市場購買了5,000,000股股份，佔已發行股份總數約0.027%，每股平均代價為2.68港元，總代價約為13,402,500港元。該批股份將由受託人代獲選參與者以信託持有。本公司董事會將繼續檢討及決定未來根據該計劃授予的股份數目及購買的股份數目。公告由公司主席謝其潤於同日發出。
China Biopharmaceuticals Limited (the “Company”) purchased 5,000,000 shares from the market through trustees on 15 April 2024 under the Restrictive Share Award Scheme adopted on 5 January 2018, representing approximately 0.027% of the total issued shares at an average price of HK$2.68 per share and a total cost of approximately HK$13,402,500 meta. The lot of shares will be held in trust by the trustee on behalf of the selected participant. The Board of Directors of the Company will continue to review and decide on the number of shares to be granted under the Plan in the future and the number of shares to be purchased. The announcement was made on the same day by the Chairman of the Company, Mr. Takei Yun.
China Biopharmaceuticals Limited (the “Company”) purchased 5,000,000 shares from the market through trustees on 15 April 2024 under the Restrictive Share Award Scheme adopted on 5 January 2018, representing approximately 0.027% of the total issued shares at an average price of HK$2.68 per share and a total cost of approximately HK$13,402,500 meta. The lot of shares will be held in trust by the trustee on behalf of the selected participant. The Board of Directors of the Company will continue to review and decide on the number of shares to be granted under the Plan in the future and the number of shares to be purchased. The announcement was made on the same day by the Chairman of the Company, Mr. Takei Yun.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more